Skip to main content
. 2017 Jun 30;31(7):625–638. doi: 10.1007/s40263-017-0443-y

Fig. 3.

Fig. 3

Incidence of treatment-emergent adverse events identified by the sponsor as of special interest: a decreased appetite, b weight decrease, c insomnia, and d headache (safety population). Percentages are based on the number of participants in the safety population who received lisdexamfetamine dimesylate for the given week. TEAE treatment-emergent adverse event